Can EyePoint (EYPT) Stock Reach $1?

EyePoint, Inc. (formerly EyePoint Pharmaceuticals), a Watertown, Massachusetts-based clinical-stage ophthalmology biopharmaceutical company, suffered a catastrophic setback when its lead drug candidate DURAVYU failed a second pivotal Phase 3 trial in wet age-related macular degeneration (wet AMD). Shares collapsed roughly 85% to an all-time low near $0.40. The question facing investors is whether a recovery toward $1 per share is realistic.

Key Takeaways

• The $1 objective is not a consensus forecast; it is the most recent verifiable post-crash analyst price target, set by Jefferies (cut to $1 from $8) after the trial failure.
• The broader pre-crash average analyst target of roughly $26 (range of about $4 to $68) is now effectively obsolete and has not been refreshed.
• EYPT closed near $0.41, meaning reaching $1 requires a gain of roughly 147% — a very large move from current levels.
• The strongest potential support is a pivot to diabetic macular edema (DME), where two Phase 3 trials (COMO and CAPRI) are expected to report in the fourth quarter of 2027.
• The biggest risks are dwindling cash, a 53% workforce reduction, and investor skepticism after two wet AMD failures.

Analyst Price Targets and the $1 Objective

Before the failure, analysts tracked by FactSet carried a consensus around a Buy rating, with 13 analysts split 54% Buy and 46% Hold, and published targets that had ranged widely — from roughly $4 to as high as $68, with an average near $26. Those figures predate the clinical setback and have not yet been updated, so they no longer reflect the company's reality.

The only clearly verifiable current target is Jefferies analyst Faisal Khurshid, who downgraded EYPT to Hold from Buy and slashed his price target to $1 from $8, calling the road to recovery "a tough path." Because no credible multi-analyst consensus exists after the failure, this article uses the $1 figure as a public, identifiable price objective rather than a calculated analyst average.

Current Market Position and Path Toward the Target

EYPT traded near $0.41, down more than 96% over the past year and off its 52-week high of $19.11. A move to $1 would require a gain of roughly 147%, a very large move that would require a fundamental re-rating, not simply a technical rebound.

The immediate path is defined by the company's strategic pivot. After DURAVYU failed to show non-inferiority to Regeneron's Eylea (aflibercept) in the LUCIA trial — improving best-corrected visual acuity by 2.5 letters versus 6 letters for the control arm — EyePoint ended its wet AMD program and is reducing its workforce by about 53% to preserve capital. Management is redirecting resources to DURAVYU in DME, where it reported roughly $118 million in cash and equivalents as of September 30, 2026.

What Could Support a Move Toward the Target

• The DME pivot: Phase 2 data in DME was encouraging, with more than 70% of patients remaining supplement-free for six months, and COMO and CAPRI are fully enrolled.
• Cash runway: roughly $118 million plus roughly $30 million in annualized savings from restructuring could fund operations toward the DME readouts.
• Secondary endpoints: LUCIA showed a 38% reduction in treatment burden and 52% of patients supplement-free at 56 weeks, which management argues supports DURAVYU's mechanism.
• Depressed valuation: with a market capitalization near $35 million versus its cash balance, any positive DME signal could trigger a sharp repricing.

What Could Prevent the Target From Being Reached

• Binary clinical risk: the two DME readouts are not expected until late 2027, leaving a long period of uncertainty.
• Efficacy doubts: analysts note that two wet AMD failures "put a cloud over how efficacious this drug is," reducing confidence in DME success.
• Cash burn: the company remains unprofitable and may need additional financing before any readout.
• Downlisting and dilution risk: a sub-$1 share price raises concerns about Nasdaq listing compliance and future equity raises that would dilute holders.

Technical Levels and Market Structure

The stock is trading at its all-time low near $0.40, having erased essentially all prior support levels in a single session. The $0.40 area is the key near-term floor, while $1 now functions as both a psychological round-number level and the reference objective. Prior support zones established during 2025 are no longer relevant, and the long-term trend structure is decisively bearish.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a 12-month research horizon, but here the decisive events are farther out: the COMO and CAPRI Phase 3 DME readouts are expected in the fourth quarter of 2027. In the nearer term, investors should monitor quarterly cash balances, any update on Nasdaq listing compliance, the completion of the restructuring, and any additional analyses of the LUCIA and LUGANO datasets. Analyst revisions — including whether others follow Jefferies lower or hold — will also matter.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like EYPT, such signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening. Traders can use the tool to supplement their own research and stay alert to momentum shifts as the DME story evolves.

Final Assessment

The $1 objective for EYPT is a post-crash, single-analyst figure rather than a consensus, reflecting a roughly 147% recovery that would depend almost entirely on renewed confidence in DURAVYU's DME program. Support rests on the company's cash position and a credible, fully enrolled DME pivot, while the obstacles — two failed wet AMD trials, a long wait until late-2027 data, and financing and listing risks — are substantial. Whether EYPT can reach $1 hinges on factors that remain unresolved and will be clarified only by future clinical and financial updates, not by any near-term forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations